Clinical trials: Etoposide, completed
Metastatic Osteosarcoma
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and kill them without harming normal cells.
- Trial name
- NCT00023998
- Testing
- doxorubicin hydrochloride, cisplatin, methotrexate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome.
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00002798
- Testing
- asparaginase, daunorubicin hydrochloride, fludarabine phosphate
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- National Cancer Institute (NCI)
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
This phase Ib trial studies the side effects of combination chemotherapy and donor stem cell transplant followed by ixazomib citrate maintenance therapy in treating patients with multiple myeloma that has returned after a period…
- Trial name
- NCT02504359
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Natural Killer (NK) Cell Transplantation for AML
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
- Trial name
- NCT00187096
- Testing
- Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
AC220 for Children With Relapsed/Refractory ALL or AML
This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).
- Trial name
- NCT01411267
- Testing
- AC220, Cytarabine, Etoposide
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Leukemia, Myeloid
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia
Primary study objective is the evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1) in terms of relapse incidence…
- Trial name
- NCT01050036
- Testing
- autologous hematopoietic cell transplantation
- Where
- 11 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of azacitidine when given together with mitoxantrone, etoposide phosphate, and cytarabine in treating patients with acute myeloid leukemia that has returned after a period…
- Trial name
- NCT01249430
- Testing
- Azacitidine, Cytarabine, Etoposide Phosphate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00345865
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 473 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Desmoplastic/Nodular Medulloblastoma, Medulloblastoma
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
This phase II trial studies how well combination chemotherapy works in treating younger patients with newly diagnosed, non-metastatic desmoplastic medulloblastoma.
- Conditions
- Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome
- Trial name
- NCT02017964
- Testing
- Carboplatin, Cognitive Assessment, Cyclophosphamide
- Where
- 173 sites in United States, Australia and 2 more
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Large B Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00118209
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 47 sites in United States
- Volunteers
- 524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkin's Lymphoma, Leukemia
Use of Topotecan in Patients With Refractory Acute Leukemia
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment.
- Trial name
- NCT00100477
- Testing
- Topotecan, Mitozantrone, Etoposide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Department of Veterans Affairs
Diffuse Large Cell Lymphoma, Lymphoma
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and…
- Trial name
- NCT00591630
- Testing
- Zevalin, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor stem cell transplant or a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from…
- Trial name
- NCT00534430
- Testing
- busulfan, cyclosporine, etoposide
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
- Trial name
- NCT00191139
- Testing
- gemcitabine, docetaxel, cisplatin
- Where
- 15 sites in United States, Argentina and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Malignant Disease
Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment…
- Trial name
- SGI-0470-02 (NCT00881166)
- Testing
- MP-470 + topotecan, MP-470 + docetaxel, MP-470 + erlotinib
- Where
- 5 sites in United States
- Volunteers
- 101 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Small Cell Lung Cancer
Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
This is a phase III, multicenter, double-blinded, placebo-controlled study of platinum（Cisplatin or Carboplatin） plus etoposide with or without toripalimab as first Line therapy in patients with extensive stage small cell lung…
- Trial name
- NCT04012606
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Lymphoma
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
RATIONALE: Giving chemotherapy and radiation therapy to the entire body before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00559104
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a four day chemotherapy regimen involving dexamethasone, cytoxan, etoposide, and cisplatinum…
- Trial name
- NCT00083681
- Testing
- Thalidomide, Dexamethasone, Cytoxan
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arkansas
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen.
- Conditions
- Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
- Trial name
- NCT02489903
- Testing
- RRx-001, Cisplatin, Etoposide
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- EpicentRx, Inc.
Prostate Cancer
Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
The aim of our study is to assess the efficacy and toxicity of a chemotherapy regimen combining carboplatin and etoposide in patients with metastatic hormone-resistant prostate cancer and neuro-endocrine differentiation.
- Trial name
- NCT00973882
- Testing
- Carboplatin, Etoposide
- Where
- 11 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard